Ligand Pharmaceuticals Incorporated (LGND) — Cash Flow Quality Index
Ligand Pharmaceuticals Incorporated (LGND) has a Cash Flow Quality Index of 0.50x as of June 2026. Operating cash flow of $24.02 Million is below net income of $48.51 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Ligand Pharmaceuticals Incorporated to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Ligand Pharmaceuticals Incorporated Cash Flow Quality Index (2007–2025)
Historical Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Ligand Pharmaceuticals Incorporated (LGND) cash flow conversion.
Annual Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated (2007–2025)
Year-by-year earnings quality comparison for Ligand Pharmaceuticals Incorporated.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.40x | $49.36 Million | $124.45 Million | ▼ -58.3% |
| 2023 | 0.95x | $49.58 Million | $52.15 Million | ▼ -31.1% |
| 2021 | 1.38x | $78.80 Million | $57.14 Million | ▲ +3058.3% |
| 2019 | -0.05x | $-29.34 Million | $629.30 Million | ▼ -103.4% |
| 2018 | 1.35x | $194.06 Million | $143.32 Million | ▼ -81.8% |
| 2017 | 7.45x | $93.57 Million | $12.56 Million | ▲ +4452.7% |
| 2015 | 0.16x | $41.73 Million | $254.93 Million | ▼ -91.3% |
| 2014 | 1.89x | $20.57 Million | $10.89 Million | ▼ -19.4% |
| 2013 | 2.34x | $20.69 Million | $8.83 Million | ▲ +2133.4% |
| 2011 | -0.12x | $-1.17 Million | $10.17 Million | ▲ +66.8% |
| 2007 | -0.35x | $-97.73 Million | $281.69 Million | — |